Tags : KEYNOTE-177

Merck & Co. Reports Results of Keytruda (pembrolizumab) in P-III

Shots: The P-III KEYNOTE-177 study involves assessing of Keytruda as monothx. vs SOC CT (mFOLFOX6/ FOLFIRI, with/out bevacizumab/ cetuximab) as a 1L treatment in 308 patients with MSI-H or dMMR advanced colorectal cancer The P-III KEYNOTE-177 study resulted in meeting its one of its dual 1EPs i.e. demonstrated significant improvement in PFS. Following the DMC’s […]Read More